[{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief therapeutics and NeuroRx File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics studies Aviptadil for Covid-19-related ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Filing of IND for Phase 2\/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UCI Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCI Health to Initiate Drug Clinical Trial to Treat Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCI Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Enrolls First Patients with RLF- 100 in Phase 2b\/3 Clinical Trial in Patients with COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NeuroRx"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Status to NeuroRx\u2019s Covid-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Ph 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics\u2019 Aviptadil gets US FDA Expanded Access Protocol to Treat Respiratory Failure in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients With Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics Holdings","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics Holdings"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100\u2122 and Selection of Commercial Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NeuroRx"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Submits Request for Emergency Use Authorization for RLF-100\u2122 for Patients with Critical Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100\u2122 (aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Announce Efficacy Data from Patients Treated with RLF-100\u2122 Under the U.S. FDA Expanded Access Protocol Authorization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Continuation of RLF-100\u2122 Trial for Treatment of COVID-19 Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief, Neuro Rx Announce Enrollment of 150 Patientsinn Phase 2b\/3 Trial of RLF-100 for Critical Covid-19 with Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NeuroRx"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Meet Patient Enrollment Target in Phase 2b\/3 Trial of RLF-100 for Critical COVID-19 with Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Stock Plunges After FDA Rejects Covid-19 Emergency Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Affirms Initiation of Phase 2\/3 Trial of Inhaled RLF-100\u2122 (aviptadil; Zyesami\u2122) in Severe Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Advita","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Relief Sings Binding Term Sheet To Acquire All Shares of AdVita to Expand the Scope of Development of Aviptadil Inhaled Formulation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Advita","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Advita \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Advita \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Initiates Phase 2\/3 Study of Inhaled ZYESAMI\u2122 for Severe COVID-19 with UCI Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Reports Initial Phase 2b\/3 Study Results of ZYESAMI in Patients with Respiratory Failure due to Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Announces ZYESAMI Met the Primary Endpoint of Its Phase 2b\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Confirms Release of 60-Day Findings from Phase 2b\/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NeuroRx"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Denk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI for COVID-19 Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ Denk Pharma","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Denk Pharma"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of Therapeutics for Severely Ill Hospitalized Covid-19 Patients Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Advita","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief and AdVita to Begin Inhaled RLF-100 Trial for Covid-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"Relief Therapeutics \/ AdVita Lifescience","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ AdVita Lifescience"},{"orgOrder":0,"company":"Senator Richard Lugar Research Institute","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharma to Develope COVID-19 Medicines and Vaccines in Central Europe in Collaboration with the Lugar Institute and Cromos Pharma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Senator Richard Lugar Research Institute","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophore seeks DCGI Emergency Use Approval of Aviptadil for Covid-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Starts Emergency Use Training and Extension of Phase 2\/3 Inhaled ZYESAM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Presents Evidence ZYESAMI\u2122 (aviptadil) Helps Prevent \"Cytokine Storm\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI\u2122 (aviptadil) in Nation of Georgia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI\u2122 (aviptadil) Inhaler for Respiratory Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharma Provides Positive Safety Update On Zyesami in NIH sponsored ACTIV-3 Critical Care Phase 3 Study in Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NRx Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ IQVIA"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI\u2122 (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI\u2122 (Aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI\u00ae (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Reports that its U.S. Collaboration Partner\u2019s Emergency Use Authorization Request for ZYESAMI\u00ae\/RLF-100\u2122 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI\u00ae (Aviptadil) Treated Patients Previously Administered Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI\u00ae and BriLife COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI\u00ae (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI\u00ae (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI\u00ae (aviptadil) in Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ NIH","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ NIH"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI\u00ae (aviptadil)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Declines Emergency Use Authorization for Zyesami\u00ae (Aviptadil) for Subgroup of Patients With Critical Covid-19 at Immediate Risk of Death From Respiratory Failure Despite Treatment With Approved Therapy, Including Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIPR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (aviptadil)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIPR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophore Applies For DCGI Approval for Emergency Use of Aviptadil to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Aviptadil Acetate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target